Ketoprofen
Pronunciation: (KEY-toe-PRO-fen)
Class: NSAID
Trade Names
Ketoprofen
- Capsules 50 mg
- Capsules 75 mg
- Capsules, extended-release 100 mg
- Capsules, extended-release 150 mg
- Capsules, extended-release 200 mg
APO-Keto-E (Canada)
APO-Keto SR (Canada)
Pharmacology
Decreases inflammation, pain, and fever, probably through inhibition of cyclooxygenase activity and prostaglandin synthesis.
Pharmacokinetics
Absorption
Immediate-release form is released in the stomach; T max is 0.5 to 2 h. Sustained-release form is released in the small intestine; T max is 6 to 7 h. Bioavailability is approximately 90%. Food does not change AUC, but the rate of absorption for either form is slowed.
Distribution
More than 99% protein bound, mainly to albumin. Vd is 0.1 L/kg.
Metabolism
Metabolic pathway is glucuronide conjugation. The metabolite is acylglucuronide, which can be converted back to the parent drug. There are no known active metabolites.
Elimination
Oral immediate release t ½ is 2 to 4 h. Sustained-release t ½ is approximately 5.4 h. Cl is approximately 0.08 L/kg/h.
Onset
Within 30 min.
Duration
Persisted for up to 6 h.
Special Populations
ElderlyPlasma and renal Cl are reduced and the unbound fraction increases.
Hypoalbuminemia and Renal Function ImpairmentPatients with these conditions may be at greater risk of adverse reactions due to increased fractions of free drug. Give these patients lower doses of the drug and monitor them closely.
Indications and Usage
Treatment of rheumatoid arthritis and osteoarthritis.
Immediate-release form onlyTreatment of mild to moderate pain and primary dysmenorrhea.
OTC UseTemporary relief of minor aches and pains associated with common cold, headache, toothache, muscular aches, backache, minor arthritis pain, menstrual cramps, and reduction of fever.
Unlabeled Uses
Treatment of juvenile rheumatoid arthritis, sunburn, migraine prophylaxis.
Contraindications
Patients in whom aspirin, iodides, or any NSAID have caused allergic-type reactions.
Dosage and Administration
Rheumatoid Arthritis or OsteoarthritisAdults Immediate-release
PO 75 mg 3 times daily or 50 mg 4 times daily; do not exceed 300 mg/day.
Maintenance doseReduce initial dosage to 75 to 150 mg/day in elderly or disabled patients or those with renal function impairment.
Sustained-releasePO 200 mg once daily can be used in patients already stabilized on that dose.
Mild to Moderate Pain, Primary DysmenorrheaAdults
PO 25 to 50 mg every 6 to 8 h as needed; do not exceed 300 mg/day.
OTC UseAdults
PO 12.5 mg with a full glass of liquid every 4 to 6 h. If pain or fever persists after 1 h, follow with 12.5 mg. Do not exceed 25 mg in a 4- to 6-h period or 75 mg in a 24-h period. Use the smallest effective dose.
ChildrenPO Do not give to children younger than 16 yr of age unless directed by a health care provider.
Mild To Severe Renal Function ImpairmentMaximum recommended total daily dose is 150 mg. In patients with more severe renal function impairment (GFR less than 25 mL/min or end-stage renal impairment), the max total daily dose should not exceed 100 mg.
Hepatic Function ImpairmentFor patients with impaired hepatic function and serum albumin concentration less than 3.5 g/dL, the max initial total daily dose should be 100 mg.
Storage/Stability
Store at room temperature in tightly closed, light-resistant container.
Drug Interactions
AnticoagulantsIncreased risk of gastric erosion and bleeding.
AspirinAdditive GI toxicity.
CyclosporineNephrotoxicity of both agents may be increased.
LithiumSerum lithium levels may be increased.
MethotrexateIncreased methotrexate levels.
Laboratory Test Interactions
May prolong bleeding time.
Adverse Reactions
Cardiovascular
Peripheral edema; fluid retention; CHF.
CNS
Headache; dizziness; lightheadedness; drowsiness; vertigo.
Dermatologic
Rash; pruritus.
EENT
Visual disturbances; stomatitis.
GI
Peptic ulcer; GI bleeding; dyspepsia; nausea; diarrhea; constipation; abdominal pain; flatulence; anorexia; vomiting.
Genitourinary
Menorrhagia.
Respiratory
Bronchospasm; laryngeal edema; rhinitis; dyspnea.
Precautions
WarningsNSAIDs may cause an increased risk of serious CV thrombotic events, MI, and stroke, which can be fatal. This risk may increase with length of therapy. Patients with CV disease or risk factors for CV disease may be at greater risk. NSAIDs cause an increased risk of serious GI adverse reactions, including bleeding, inflammation, perforation of the stomach or intestines, and ulceration, which can be fatal. These events can occur any time during use and without warning symptoms. Elderly patients are at greater risk of serious GI events. |
Pregnancy
Category B .
Lactation
Excreted in breast milk.
Children
Safety and efficacy not established.
Elderly
Increased risk of adverse reactions.
Hypersensitivity
Hypersensitivity may occur; use caution in aspirin-sensitive individuals because of possible cross-sensitivity.
Renal Function
Lower doses may be necessary.
Hepatic Function
Avoid sustained-release product.
GI
Bleeding, ulceration or perforation can occur at any time, with or without warning symptoms.
GU
Acute renal insufficiency, interstitial nephritis, hyperkalemia, hyponatremia and renal papillary necrosis may occur.
Overdosage
Symptoms
Drowsiness, dizziness, confusion, disorientation, lethargy, numbness, vomiting, gastric irritation, nausea, abdominal pain, headache, tinnitus, convulsions, acute renal failure.
Patient Information
- Advise patient to take medication with food, milk, or antacids. Capsule should be swallowed whole, not chewed or crushed.
- Warn patient not to take aspirin or other NSAIDs.
- Caution patient to report changes in stool (eg, color, consistency, frequency), fluid retention and shortness of breath.
- Instruct patient to report the following symptoms to health care provider: skin rash, itching, visual disturbances, weight gain, edema, black stools, or persistent headache.
- Advise patient that drug may cause drowsiness and to use caution while driving or performing other tasks requiring mental alertness.
- Caution patient to avoid exposure to sunlight and other sources of ultraviolet light and to use sunscreen or wear protective clothing to avoid photosensitivity reaction.
- Instruct patient not to ingest alcohol or take OTC medications without notifying health care provider.
Copyright © 2009 Wolters Kluwer Health.
More Ketoprofen resources
- Ketoprofen Prescribing Information (FDA)
- Ketoprofen MedFacts Consumer Leaflet (Wolters Kluwer)
- Ketoprofen Monograph (AHFS DI)
- ketoprofen Advanced Consumer (Micromedex) - Includes Dosage Information
- ketoprofen Concise Consumer Information (Cerner Multum)
- Orudis Prescribing Information (FDA)
- Oruvail Extended-Release Capsules MedFacts Consumer Leaflet (Wolters Kluwer)



